Letter to the editor: Key safety parameters from the literature on pegloticase with immunomodulation

Semin Arthritis Rheum. 2021 Dec;51(6):1386-1388. doi: 10.1016/j.semarthrit.2021.11.005.

Authors

Jeff Peterson¹, Nathan Roe², Lissa Padnick-Silver², Howard Kenney³, Abdul Abdellatif⁴, Brian LaMoreaux⁵

Affiliations

¹ Western Washington Arthritis Clinic, Bothell, WA.
² Horizon Therapeutics plc, Deerfield, IL.
³ Arthritis Northwest, PLLC, Spokane, WA.
⁴ Baylor College of Medicine, Webster, TX.
⁵ Horizon Therapeutics plc, Deerfield, IL. Electronic address: blamoreaux@horizontherapeutics.com.

PMID: 34906369
DOI: 10.1016/j.semarthrit.2021.11.005

No abstract available

Keywords: adverse events; immunomodulation; pegloticase; safety.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Gout Suppressants / therapeutic use
Gout* / drug therapy
Humans
Immunomodulation
Polyethylene Glycols / therapeutic use
Urate Oxidase* / therapeutic use

Substances

Gout Suppressants
Polyethylene Glycols
Urate Oxidase
Pegloticase